Moderna and Merck's Cancer Vaccine Breakthrough Sparks Hope for Personalized Medicine

Moderna and Merck have made a groundbreaking breakthrough in cancer vaccine research after over 100 years of failed attempts. The mRNA-based vaccine, developed through a partnership between the two companies, has shown promising results in late-stage testing.

The vaccine, known as intismeran autogene, trains the immune system to attack cancer cells by targeting mutations unique to each patient's tumors. In a trial involving over 1,000 patients with localized melanoma, the vaccine kept tumors from coming back or spreading.

Merck paid $200 million upfront in 2016 and another $250 million in 2022 for the rights to develop the cancer vaccine. The companies share costs and profits. With full trial details pending, Wall Street is already estimating billions of dollars in sales.